Hybrid Nanovesicles Combine Light Therapy with Immune Boost to Fight Melanoma

Phototherapy shows promise for treating skin melanoma but faces significant challenges including cellular resistance to cell death, oxygen-starved tumor environments, and abnormal blood vessel formation. These limitations reduce treatment effectiveness and allow tumors to survive.

Researchers at Shandong University designed a novel hybrid delivery system called IHEL that combines macrophage-derived exosomes with liposomes to carry two therapeutic agents: hemin and IR780. This system specifically targets melanoma tumors while simultaneously reprogramming the hostile tumor microenvironment.

The key innovation involves hemin triggering iron overload in cancer cells, which activates a secondary cell death pathway called ferroptosis alongside the traditional apoptosis pathway activated by IR780 phototherapy. This dual approach helps overcome cellular resistance mechanisms that allow tumors to survive single-pathway treatments. Hemin also acts like the enzyme catalase, breaking down hydrogen peroxide to release oxygen and reducing the oxygen-starved conditions that limit phototherapy effectiveness.

Beyond direct tumor killing, IHEL activates the immune system by triggering immunogenic cell death, which alerts immune cells to attack remaining cancer cells. The treatment also reprograms tumor-associated macrophages from cancer-supporting to cancer-fighting types and disrupts the abnormal sugar metabolism that fuels tumor growth. This comprehensive approach addresses multiple tumor survival mechanisms simultaneously, potentially improving long-term treatment outcomes for melanoma patients.